Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
MSA - Multiple System Atrophy: later-stage trial registry
2 of 4 indexed MSA - Multiple System Atrophy trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
MSA - Multiple System Atrophy: 4 US clinical trials tracked, 2 recruiting.
MSA - Multiple System Atrophy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition msa-multiple-system-atrophy
OPEN 2 | RECR 50% | LATE 1 | EARLY 0 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
MSA - Multiple System Atrophy lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for MSA - Multiple System Atrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
MSA - Multiple System Atrophy is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Modifiable Variables in Parkinsonism (MVP)
Bastyr University
NCT02194816
The CurePSP Genetics Program
Massachusetts General Hospital
NCT06647641
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Theravance Biopharma
NCT05696717
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Massachusetts General Hospital
NCT04753320
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on MSA - Multiple System Atrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on MSA - Multiple System Atrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this MSA - Multiple System Atrophy page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 MSA - Multiple System Atrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most MSA - Multiple System Atrophy trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MSA - Multiple System Atrophy condition card totals 4 registered trials; most-linked intervention Ampreloxetine; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.